Kicking Genomic Profiling to the Curb: How Re-wiring the Phosphoproteome Can Explain Treatment Resistance in Glioma  Fred C. Lam, Michael B. Yaffe  Cancer Cell  Volume 29, Issue 4, Pages 435-436 (April 2016) DOI: 10.1016/j.ccell.2016.03.022 Copyright © 2016 Elsevier Inc. Terms and Conditions

Figure 1 Single-Cell Phosphoproteomic Profiling of Treatment-Resistant Patient-Derived GBM Xenografts Reveals Early Re-wiring of Signaling Pathways without Genomic Mutations Mice containing drug-naive patient-derived xenografts (PDX) were treated with an mTOR kinase inhibitor (mTORki). Resistant tumor cells after treatment were analyzed by immunohistochemistry and single-cell phosphoproteomic profiling with an SCBC chip, revealing re-wiring of critical signaling nodes as the mechanism of resistance. Treatment of drug-naive PDX with combination therapies that blocked these re-wired nodes effectively eliminated the development of resistance to mTOR inhibition. Cancer Cell 2016 29, 435-436DOI: (10.1016/j.ccell.2016.03.022) Copyright © 2016 Elsevier Inc. Terms and Conditions